help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2573
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/5/1600    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Zapf, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Zapf, J.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 5 1600-1605
Copyright © 2007 by The Endocrine Society

CLINICAL CASE SEMINAR

Hypoglycemia due to Paraneoplastic Secretion of Insulin-Like Growth Factor-I in a Patient with Metastasizing Large-Cell Carcinoma of the Lung

Michael A. Nauck, Manfred Reinecke, Aurel Perren, Jan Frystyk, Giorgi Berishvili, Cornelia Zwimpfer, Anja M. Figge, Allan Flyvbjerg, Paul G. Lankisch, Werner F. Blum, Günter Klöppel, Wolff Schmiegel and Jürgen Zapf

Department of Medicine (M.A.N., A.M.F., W.S.), Ruhr-University, Knappschafts-Krankenhaus, D-44892 Bochum, Germany, and Diabeteszentrum Bad Lauterberg (M.A.N.), D-37431 Bad Lauterberg im Harz, Germany; Division of Neuroendocrinology (M.R., G.B., J.Z.), Institute of Anatomy, University of Zurich, and Department of Internal Medicine (C.Z., J.Z.), University Hospital, Zurich, Switzerland; Institute of Pathology (A.P.), University Hospital, CH-8057 Zürich, Switzerland; Medical Research Laboratories (J.F., A.F.), Institute of Experimental Clinical Research, Aarhus University Hospital, DK-8000 Aarhus, Denmark; Department of Internal Medicine (P.G.L.), Städtische Kliniken D-21339 Lüneburg, Germany; Department of Pediatrics (W.F.B.), University of Giessen, Giessen, and Eli Lilly & Co., D-61350 Bad Homburg, Germany; and Department of Pathology (G.K.), Christian-Albrecht-University, D-24105 Kiel, Germany

Address all correspondence and requests for reprints to: Michael A. Nauck, M.D., Diabeteszentrum Bad Lauterberg, Kirchberg 21, D-37431 Bad Lauterberg, Germany. E-mail: M.Nauck{at}diabeteszentrum.de.


   Abstract
Top
 Abstract
Introduction
 Patient and Methods
 Results
 Discussion
 References
 
Context: Nonpancreatic tumors may cause recurrent hypoglycemia known as nonislet cell tumor hypoglycemia. It is due to overproduction and secretion by the tumor of incompletely processed IGF-II, termed big IGF-II. We recently identified a patient with recurrent hypoglycemia and low insulin, but without elevated big IGF-II. Multiple small lung nodules were detected by computed tomography scan. An undifferentiated large-cell carcinoma was diagnosed from an axillary lymph node metastasis.

Objective: The objective was to investigate whether the patient’s hypoglycemia was due to excessive IGF-I production by the tumor.

Methods: Serum IGF- I and IGF-II, insulin, and GH were measured by RIA; the distribution of IGFs between IGF binding protein complexes in serum was analyzed after neutral gel filtration. Tissue IGF-I was identified by immunohistochemistry and in situ hybridization, and by RT-PCR after RNA extraction.

Results: Total and free serum IGF-I, but not total, free, and big IGF-II, was increased, and the IGF-I content of the two IGF binding protein complexes was elevated. Immunohistochemistry demonstrated IGF-I peptide in situ hybridization IGF-I mRNA in the lymph node metastasis. Combined GH/glucocorticoid treatment prevented hypoglycemia, but did not lower IGF-I. After chemotherapy with carboplatinum/etoposide, the lung nodules largely regressed, and serum IGF-I and the IGF-I content of the two binding protein complexes became normal. Hypoglycemia did not recur despite discontinuation of GH/glucocorticoid treatment.

Conclusion: Our findings are compatible with a new form of tumor hypoglycemia caused by circulating tumor-derived IGF-I.


   Introduction
Top
 Abstract
 Introduction
Patient and Methods
 Results
 Discussion
 References
 
TUMORS NOT DERIVED from pancreatic islets may produce recurrent fasting hypoglycemia, a condition called nonislet cell tumor hypoglycemia (NICTH) (1, 2, 3, 4, 5). The tumors can be mesenchymal or epithelial and, in rare cases, hematopoietic (1, 2, 3). They are usually large (weighing more than 500 g), well-differentiated, and slowly growing, and can be benign or malignant (1, 2, 4).

NICTH often results from the overproduction and secretion by the tumor of incompletely processed or unprocessed pro-IGF-II peptide (6, 7, 8), termed "big" IGF-II (molecular mass, 10–17 kDa, in contrast to mature IGF-II of 7.5 kDa). Big IGF-II impairs formation of a heterotrimeric 150-kDa IGF binding protein (IGFBP) complex in the circulation (9), which consists of IGF-I, IGF-II, IGFBP-3, and an acid-labile subunit (ALS). In normal individuals, most of the circulating IGFs are bound to this complex. Thereby, IGFs are prevented from displaying their insulin-like potential. However, when formation of the 150-kD complex is impaired, IGFs are sequestered in a binary complex with IGFBP-3 (7). In the latter complex, the bioavailability of IGFs is increased and their insulin-like potential is unmasked leading to enhanced peripheral glucose consumption (10, 11, 12) and suppressed hepatic glucose production (10, 11). Typically, serum insulin levels are low or unmeasurable in NICTH, and serum GH levels are suppressed.

Patients with clinical NICTH do not always present with elevated "big" IGF-II (13). Some cases are due to ectopic insulin production, e.g. from a bronchial carcinoid (14), and ovarian carcinoma (15), or a small-cell carcinoma of the cervix (16).

So far, hypoglycemia due to an IGF-I-producing tumor has not been reported. We recently identified a patient with severe recurrent hypoglycemia who had elevated IGF-I but normal big IGF-II serum levels. Extensive clinical testing excluded an insulinoma, as well as pituitary or adrenal insufficiency. We therefore set out to investigate whether the patient’s recurrent hypoglycemia was due to overproduction and secretion of IGF-I by a tumor and to characterize a hitherto undiscovered form of NICTH.


   Patient and Methods
Top
 Abstract
 Introduction
 Patient and Methods
Results
 Discussion
 References
 
Patient

A 64-yr-old woman was admitted to the emergency room in February 1999. She was unconscious and had convulsions. Hypoglycemia was diagnosed and corrected by iv glucose administration. Hypoglycemia frequently recurred, especially during the night.

The patient had a history of Sjögren syndrome (lymphocytic sialadenitis with xerostoma) but was otherwise healthy. She was slightly overweight (76.6 kg, 168 cm, body mass index 27.1 kg/m2) and had no signs of acromegaly. No abdominal mass or enlarged lymph nodes were palpated. A chest x-ray, an abdominal ultrasound, a mammography, and a somatostatin receptor scintigraphy did not show any tumor. Liver and kidney function was unimpaired. Thyroid disease and pituitary or adrenal insufficiency were excluded.

Treatment

Because serum IGF-I was elevated, GH and big IGF-II were normal, and serum insulin and C-peptide were suppressed, we considered IGF-I-induced tumor hypoglycemia, although no tumor had initially been found. Therefore, in analogy to IGF-II-induced tumor hypoglycemia, treatment with GH (17.4 µg/kg·d im Norditropin; NovoNordisk, Mainz, Germany) and prednisone (40 mg/d) (9), was started. Hypoglycemic episodes ceased. GH and prednisone were gradually tapered to 5.2 µg/kg·d and 2.5 mg/d, respectively. This dose was given until October 2004.

Seven months after the first admission, the patient palpated a mass in the right axilla. A lymph node (diameter, 3.5 cm) was surgically removed. Histological examination revealed an undifferentiated large-cell carcinoma. A computed tomography scan showed several small nodules in the right lung. Sequential therapy with Gemcitabin/Vinorelbine, Docetaxel, and Iressa (a vascular endothelial growth factor receptor antagonist) failed to stop further dissemination in the lungs despite transient partial remission. Finally, treatment with four cycles of carboplatinum (500 mg)/etoposide (190 mg) from December 2003 to March 2004 led to the disappearance of the lung nodules as documented by computed tomography. GH and prednisone was stopped in October 2004, and hypoglycemia did not recur. Fasting was tolerated for 24 h, and 24-h profiles of glucose, insulin, and C-peptide concentrations showed normal values throughout the day (Fig. 1Go). In 2005 a cerebellar metastasis was surgically removed, and the patient died in 2006.


Figure 1
View larger version (25K):
[in this window]
[in a new window]

  		FIG. 1. Plasma glucose (A), insulin (B), and C-peptide (C) during prolonged fasting performed during initial evaluation in February 1999 on two occasions (first test, red symbols; second test, orange symbols). Symptomatic hypoglycemia occurred early (arrow) after the last meal (at t = 0 h) and was accompanied by a complete suppression of insulin (<1.5 mU/liter) and C-peptide (<0.15 nmol/liter) at plasma glucose less than 56 mg/dl. For comparison, a 24-h fast after successful chemotherapy (October 2004) is shown (green symbols).

 
Methods

Glucose was measured by the glucose oxidase method. Plasma insulin was determined by a microparticle enzyme immunoassay (IMx Insulin; Abbott Laboratories, Wiesbaden, Germany), C-peptide by ELISA (Dako Diagnostics Ltd., Cambridgeshire, UK). Total serum IGF-I was determined by RIA (17) after chromatography of serum samples over Sep-Pak C18 cartridges (Waters Corp., Milford, MA). Free IGF-I and IGF-II levels were determined as described previously (8). Total ALS was determined by ELISA (Diagnostic Systems Laboratories, Webster, TX). GH was measured using Immulite hGH (EURO/DPC; Llanberis, Gwynedd, UK). IGFBP-1, IGFBP-2, and IGFBP-3 were determined by RIA as described (18, 19).

Gel filtration. Acidic Biogel P-60 gel filtration (Bio-Rad Laboratories, Richmond, CA) and neutral (pH 7.4) Sephadex G-200 gel filtration (Pharmacia LKB Biotechnology Inc., Uppsala, Sweden) were performed as described (7). IGF-I and IGF-II in pooled fractions were measured by RIA (17) after chromatography over Sep-Pak C18 cartridges (Waters Corp.). SDS-PAGE and ligand blot analysis were performed as described (20).

Histology and immunohistochemistry. Four-micrometer sections from formalin-fixed paraffin-embedded resection specimens (axillary lymph node) were stained with hematoxylin-eosin and periodic acid Schiff reagent. IGF-I peptide was identified by immunohistochemistry (21).

In situ hybridization. Digoxigenin-labeled probes for in situ hybridization were prepared by in vitro transcription. Templates were generated by PCR amplification of total RNA using human IGF-I-specific reverse and forward primers with T7 and T3 RNA polymerase binding sites attached to the five prime ends (21): T7, reverse primer: GGATCCTAATACGACTCACTATAGG-GCATGTCGGTGTGGC; T3, forward primer: AAT TAA CCC TCA CTA AAG G-CA GTC TTC CAA CCC AAT.

The primers amplify a segment of 374 nucleotides spanning the B and C domains and the first half of the A domain. From the promoter sequences, antisense and sense probes were transcribed using the digoxigenin in vitro transcription kit (Roche, Basel, Switzerland) as described (21).

Identification of IGF-I by PCR

RT-PCR primers spanned intron 1 of the IGF-I gene or the GAPDH gene (IGF-I forward: 5'-CTGAGCTGGTGGATGCTCTT-3'; IGF-I reverse: 5'-CACTGCTGGAGCCATACCC-3'; GAPDH forward: 5'-CCATGGAGAAGGCTGGGG-3'; GAPDH reverse: 5'-TTCACACCCATGACGAACAT-3'), leading to PCR products of 84 bp and 97 bp, respectively. RNA was extracted from paraffin-embedded tissue (22). RNA from a papillary thyroid carcinoma and blood leukocytes was used as positive and negative controls. After RT, semiquantitative RT-PCR was performed, and 5 µl of the amplificate after 30, 35, 40, and 45 PCR cycles was loaded on a 2% agarose gel. The bands for IGF-I products were excised, purified, and cycle-sequenced (22).


   Results
Top
 Abstract
 Introduction
 Patient and Methods
 Results
Discussion
 References
 
Fasting led to severe neuroglucopenic symptoms after 6 h at plasma glucose levels of 35 and 28 mg/dl on two different occasions. Insulin and C-peptide concentrations fell below their detection limit (Fig. 1Go).

IGFs and IGFBPs (Table 1Go)

On admission of the patient, total and free serum IGF-I was increased (692 ng/ml and 27.2 ng/ml, respectively), whereas total and free IGF II was normal (548 and 0.73 ng/ml). Four weeks after initiating GH/prednisone treatment, total and free IGF-I was still elevated. However, after chemotherapy with carboplatinum/etoposide and discontinuation of GH/prednisone treatment (October 2004), total IGF-I had fallen to 283 ng/ml. Total IGF-II stayed within the normal range. IGFBP-1 and IGFBP-2 were decreased. IGFBP-3 was normal but rose during GH/prednisone treatment.


View this table:
[in this window]
[in a new window]

  		TABLE 1. IGF-I, IGF-II, and IGFBPs before treatment, 4 wk after symptomatic therapy with GH and prednisone, and 7 months after chemotherapy with carboplatinum/etoposide (500/190 mg)

 
On acidic gel filtration of serum on Biogel P-60, the patient’s IGF-I eluted at the same molecular size as IGF-I of normal serum, and there was no evidence for a large molecular weight form of IGF-I (data not shown). Although the IGF-II content determined by this method was in the high normal range, big IGF-II was normal (8.3% of total IGF-II) and remained unchanged after the final chemotherapy (9.9% of total IGF-II).

The patient’s ternary (150 kDa) and binary (50 kDa) IGFBP complexes obtained by neutral Sephadex G-200 gel filtration each contained more IGF-I than the corresponding complexes of normal serum (Fig. 2AGo). IGF-II in the 150-kDa complexes of the two sera was similar; the 50-kDa complex of the patient’s serum contained somewhat less IGF-II than that of the normal serum (Fig. 2BGo). After the last chemotherapy, the IGF-I content of either complex was similar to that of normal serum. As shown by ligand blotting of the Sephadex G-200 serum fractions (Fig. 2Go, C and D), most of the IGFBP-3 was associated with the 150-kDa complex in both the patient’s serum and normal serum.


Figure 2
View larger version (33K):
[in this window]
[in a new window]

  		FIG. 2. Sephadex G-200 gel filtration at neutral pH of 1 ml of normal serum (blue symbols), and of the patient’s serum during initial evaluation in February 1999 (red symbols) and after successful chemotherapy in October 2004 (green symbols). Fractions were pooled as indicated, dialyzed against 0.1 M NH4 HCO3, lyophilized, and dissolved in 1 ml H2O. RIA for IGF-I (A) and IGF-II (B) was performed at different dilutions after passage of the pooled fractions over Sep-Pak cartridges (7 ). Lower panels, 125I-IGF-II ligand blots of pooled fractions (two fractions each) after neutral Sephadex G-200 gel filtration of the sera. Pooled fractions were treated as described; 20 µl of each pool was electrophoresed and further processed as described (16 ). C, Normal serum. D, Patient’s serum. Fractions 40–56 correspond to the 150-kDa binding protein, and fractions 57–75 to the 50-kDa binding protein peak. Lane 1, Molecular weight markers. Lanes 2 and 3, Whole normal serum (N) and patient’s serum (P) from February 1999.

 
GH secretion. Random GH concentrations were 3.0 ± 1.6 µg/liter (n = 3). Oral glucose (75 g) suppressed GH to 0.5 µg/liter. Intravenous arginine (0.5 g per kg body weight infused over 30 min) or GHRH (50 µg; Ferring Arzneimittel GmbH, Kiel, Germany) failed to stimulate GH.

IGF-I peptide and mRNA in the tumor metastasis. Immunohistochemistry demonstrated IGF-I peptide in some tumor cells as well as in extratumoral tissue (Fig. 3AGo). IGF-I mRNA was detected by in situ hybridization in virtually all tumor cells and much less frequently in extratumoral tissue (Fig. 3BGo). In the latter, the number of positive cells was in a similar range as that found by immunohistochemistry. mRNA extracted from the tumor-infiltrated lymph node, reverse-transcribed, and amplified by PCR (Fig. 3CGo) gave the cDNA sequence of a fragment that was identical to intron 1 of the published IGF-I cDNA sequence.


Figure 3
View larger version (73K):
[in this window]
[in a new window]

  		FIG. 3. Biopsy of an axillary lymph node metastasis. A, IGF-I immunohistochemistry. Heavy arrows (red) indicate IGF-I-positive tumor cells, and light arrows (yellow) point at IGF-I-positive cells in extratumoral tissue. B, IGF-I mRNA (in situ hybridization). Virtually all tumor cells are positive for IGF-I mRNA. IGF-I mRNA is also found in extratumoral cells, as indicated by light blue arrows. C, PCR of mRNA extracted and transcribed from tumor-infiltrated lymph node. The number of PCR cycles is given. GAPDH, Glyceraldehyde dehydrogenase.

 

   Discussion
Top
 Abstract
 Introduction
 Patient and Methods
 Results
 Discussion
References
 
Our patient suffered from severe recurrent nonhyperinsulinemic hypoglycemia. After excluding pituitary or adrenal insufficiency, we first considered IGF-II-induced NICTH. However, an obvious large tumor mass typical for this syndrome was absent, and serum concentrations of free, total, and big IGF-II, as well as IGFBP-3 and the ALS, were within the normal range, whereas IGFBP-1 and IGFBP-2 were decreased. These findings differ essentially from findings in IGF-II-related hypoglycemia (3, 7, 8), where free and big IGF-II is increased, IGFBP-3 and ALS are decreased, and IGFBP-1 and IGFBP-2 are elevated (3, 7, 8, 9). Furthermore, in striking contrast to IGF-II-related NICTH, where IGF-I serum concentrations are usually below normal, total and free IGF-I was elevated. In fact, IGF-I serum levels similar to those found in our patient have been shown to cause hypoglycemia upon sc infusion of IGF-I (23).

The lymph node metastasis detected several months after the first hypoglycemic symptoms most likely originated from a pulmonary large cell carcinoma. The metastasis expressed IGF-I mRNA in nearly all tumor cells but contained only small amounts of immunoreactive IGF-I peptide. These findings suggest a high rate of newly synthesized IGF-I, which was rapidly released from the tumor into the circulation, resulting in elevated total and free IGF-I serum concentrations and finally in hypoglycemia. The failure of GH to rise after arginine and GHRH administration is probably due to feedback inhibition through circulating tumor-derived IGF-I (23, 24, 25). The absence of acromegalic features in our patient may be explained by 1) the absence of a sustained combined elevation of GH and IGF-I (Table 1Go); 2) the relatively short duration of paraneoplastic hormonal changes; 3) a relatively high background insulin sensitivity; and 4) hormonal changes induced by repeated hypoglycemic episodes added on to chronic elevations in IGF-I.

Normally, 80–90% of the circulating IGF-I and IGF-II is bound to IGFBP-3 and ALS in a ternary 150-kDa complex. In big IGF-II-related NICTH, big IGF-II impairs the formation of the 150-kDa complex (9). IGF is thereby sequestered into a binary 50-kDa complex (3, 8). In this complex the bioavailability of the bound IGF is enhanced (26) because it can cross the capillary wall (27) and reach insulin target tissues to exert insulin-like effects. Indeed, the patient’s 50-kDa complex contained a 3-fold higher amount of IGF-I than the 50-kDa complex of normal serum. In combination with the elevated concentration of free IGF-I, this has probably contributed to the development of hypoglycemia.

The same symptomatic therapy (GH and glucocorticoids) as in IGF-II-mediated NICTH was effective in our patient. The mechanisms likely include GH-induced stimulation of IGFBP-3 (28), which may have prevented sequestration of free IGF-I, but above all GH-induced and glucocorticoid-induced insulin resistance (29, 30) and, thus, resistance to the insulin-like actions of IGF-I. IGF-I was not further elevated by GH treatment, indicating that IGF-I secretion from the tumor was autonomous and, therefore, relatively independent from GH as a stimulus. After successful chemotherapy, when GH treatment was discontinued, IGF-I concentrations fell, almost into the normal range.

After "successful" chemotherapy and after stopping GH/prednisone treatment, total serum IGF-I had fallen into the normal range, the IGF-I content of the 50-kDa complex was no longer elevated, and hypoglycemic episodes did not recur. All of these findings support the conclusion that secreted paraneoplastic IGF-I had caused hypoglycemia.


   Acknowledgments
 
The authors thank Dr. Dirkes-Kersting, Hygieneinstitut des Ruhrgebietes (Direktor: Prof. Dr. N. Dickgießer), Gelsenkirchen, Germany, for the measurement of GH, and S. Richter, S. Schminkel, and Th. Gottschling for help with laboratory analyses. The help of Priv. Doz. Dr. M. König and Prof. Dr. L. Heuser, Department of Radiology, Universitätsklinik Knappschaftskrankenhaus (Bochum-Langendreer) with radiological procedures (sialography, selective canulation of veins) is acknowledged. Dr. A. El-Oughlidi is acknowledged for coordinating metabolic tests and laboratory analyses.


   Footnotes
 
This study was supported by Grant 32-46808 (to J.Z.) of the Swiss National Science Foundation.

Disclosure Statement: The authors have no conflict of interest to declare in relation to the content of this manuscript.

First Published Online February 13, 2007

Abbreviations: ALS, Acid-labile subunit; IGFBP, IGF binding protein; NICTH, nonislet cell tumor hypoglycemia.

Received November 22, 2006.

Accepted February 1, 2007.


   References
Top
 Abstract
 Introduction
 Patient and Methods
 Results
 Discussion
 References
 

  1. Kahn CR 1980 The riddle of tumour hypoglycaemia revisited. Clin Endocrinol Metab 9:335–360[Medline]
  2. Marks V, Teale JD 1991 Tumours producing hypoglycaemia. Diabetes Metab Rev 7:79–91[Medline]
  3. Zapf J 1995 Insulin-like growth factor binding proteins and tumor hypoglycemia. Trends Endocrinol Metab 6:37–42[Medline]
  4. Lloyd RV, Erickson LA, Nascimento AG, Klöppel G 1999 Neoplasms causing nonhyperinsulinemic hypoglycemia. Endocr Pathol 10:291–297[Medline]
  5. Le Roith D 1999 Tumor-induced hypoglycemia. N Engl J Med 341:757–758[Free Full Text]
  6. Daughaday WH, Emanuelle MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P 1988 Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 319:1434–1440[Abstract]
  7. Zapf J, Futo E, Peter M, Froesch ER 1992 Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 90:2574–2584[Medline]
  8. Frystyk J, Skjaerbaek C, Zapf J, Ørskov H 1998 Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia 41:589–594[CrossRef][Medline]
  9. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W 1995 Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 80:2700–2708[Abstract]
  10. Jakob A, Meyer UA, Flury R, Ziegler WH, Labhart A, Froesch ER 1967 The pathogenesis of tumour hypoglycaemia: blocks of hepatic glucose release and of adipose tissue lipolysis. Diabetologia 3:506–514[CrossRef][Medline]
  11. Moller N, Blum WF, Mengel A, Hansen LB, Alberti KG, Schmitz O 1991 Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evidence for increased muscle glucose uptake. Diabetologia 34:17–20[CrossRef][Medline]
  12. Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F, Roberts Jr CT, Shapiro J, Roth J 1992 Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest 89:1958–1963[Medline]
  13. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K 2006 Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 16:211–216[CrossRef][Medline]
  14. Shames JM, Dhurandhar NR, Blackard WG 1968 Insulin-secreting bronchial carcinoid with widespread metastases. Am J Med 44:632–637[CrossRef][Medline]
  15. O’Neill RT, Mikuta JJ 1970 Hypoglycemia associated with serous cystadenocarcinoma of the ovary. Obstet Gynecol 35:287–289[Abstract/Free Full Text]
  16. Seckl MJ, Mulholland PJ, Bishop AE, Teale JD, Hales CN, Glaser M, Watkins S, Seckl JR 1999 Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 341:733–736[Free Full Text]
  17. Zapf J, Walter H, Froesch ER 1981 Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 68:1321–1330[Medline]
  18. Breier BH, Milsom SR, Blum WF, Schwander J, Gallaher BW, Gluckman PD 1993 Insulin-like growth factors and their binding proteins in plasma and milk after growth hormone-stimulated galactopoiesis in normally lactating women. Acta Endocrinol 129:427–435[Medline]
  19. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR 1990 A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70:1292–1298[Abstract]
  20. Zapf J, Schmid C, Guler HP, Waldvogel M, Hauri C, Futo E, Hossenlopp P, Binoux M, Froesch ER 1990 Regulation of binding proteins for insulin-like growth factors (IGF) in humans. J Clin Invest 86:952–961[Medline]
  21. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J 2000 Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I mRNA and peptide in rat tibial growth mplate and articular chondrocytes in vivo. Endocrinology 141:2847–2853[Abstract/Free Full Text]
  22. Maier-Woelfle M, Brandle M, Komminoth P, Saremaslani P, Schmid S, Locher T, Heitz PU, Krull I, Galeazzi RL, Schmid C, Perren A 2004 A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas. J Clin Endocrinol Metab 89:362–367[Abstract/Free Full Text]
  23. Guler H-P, Zapf J, Schmid C, Froesch ER 1989 Insulin-like growth factor I and II in healthy man. Acta Endocrinol 121:753–758
  24. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER 1993 Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249–2256[Medline]
  25. Bermann M, Jaffe CA, Tsai W, DeMott-Friberg R, Barkan AL 1994 Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. J Clin Invest 94:138–145[Medline]
  26. Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA 1995 Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 95:179–186[Medline]
  27. Binoux M, Hossenlopp P 1988 Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 67:509–514[Abstract]
  28. Teale JD, Blum WF, Marks V 1992 Alleviation of non-islet cell tumour hypoglycaemia by growth hormone therapy is associated with changes in IGF-binding protein-3. Ann Clin Biochem 29:314–323[Medline]
  29. Rizza RA, Mandarino L, Gerich JE 1982 Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669[Abstract]
  30. Rizza RA, Mandarino LJ, Gerich JE 1982 Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54:131–138[Abstract]



This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Ashare, A. B. Nymon, K. C. Doerschug, J. M. Morrison, M. M. Monick, and G. W. Hunninghake
Insulin-like Growth Factor-1 Improves Survival in Sepsis via Enhanced Hepatic Bacterial Clearance
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 149 - 157.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. H. Daughaday
Hypoglycemia due to Paraneoplastic Secretion of Insulin-Like Growth Factor-I
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1616 - 1616.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/5/1600    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Zapf, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Zapf, J.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Endocrine Oncology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals